KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) R&D In Process (2016 - 2025)

Jazz Pharmaceuticals has reported R&D In Process over the past 10 years, most recently at $42.5 million for Q3 2025.

  • Quarterly results put R&D In Process at $42.5 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $947.9 million (up 9378.62% YoY), and the annual figure for FY2025 was $947.9 million, up 9378.62%.
  • R&D In Process for Q3 2025 was $42.5 million at Jazz Pharmaceuticals, down from $905.4 million in the prior quarter.
  • Over the last five years, R&D In Process for JAZZ hit a ceiling of $905.4 million in Q2 2025 and a floor of $1.0 million in Q1 2023.
  • Median R&D In Process over the past 4 years was $30.2 million (2023), compared with a mean of $137.6 million.
  • Biggest five-year swings in R&D In Process: tumbled 64.0% in 2023 and later skyrocketed 900.0% in 2024.
  • Jazz Pharmaceuticals' R&D In Process stood at $50.0 million in 2022, then tumbled by 64.0% to $18.0 million in 2023, then plummeted by 44.44% to $10.0 million in 2024, then skyrocketed by 325.0% to $42.5 million in 2025.
  • The last three reported values for R&D In Process were $42.5 million (Q3 2025), $905.4 million (Q2 2025), and $10.0 million (Q1 2024) per Business Quant data.